BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 31114346)

  • 1. High CD3D/CD4 ratio predicts better survival in muscle-invasive bladder cancer.
    Shi MJ; Meng XY; Wu QJ; Zhou XH
    Cancer Manag Res; 2019; 11():2987-2995. PubMed ID: 31114346
    [No Abstract]   [Full Text] [Related]  

  • 2. CD3D Is an Independent Prognostic Factor and Correlates With Immune Infiltration in Gastric Cancer.
    Yuan L; Xu J; Shi Y; Jin Z; Bao Z; Yu P; Wang Y; Xia Y; Qin J; Zhang B; Yao Q
    Front Oncol; 2022; 12():913670. PubMed ID: 35719985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD19
    Jiang Q; Fu Q; Chang Y; Liu Z; Zhang J; Xu L; Zhu Y; Wang Y; Zhang W; Xu J
    Cancer Immunol Immunother; 2019 Jan; 68(1):45-56. PubMed ID: 30259082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative Assessment of Tumor-Infiltrating Lymphocytes Using Machine Learning Predicts Survival in Muscle-Invasive Bladder Cancer.
    Zheng Q; Yang R; Ni X; Yang S; Jiao P; Wu J; Xiong L; Wang J; Jian J; Jiang Z; Wang L; Chen Z; Liu X
    J Clin Med; 2022 Nov; 11(23):. PubMed ID: 36498655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Presence of lymphocytic infiltrate cytotoxic T lymphocyte CD3+, CD8+, and immunoscore as prognostic marker in patients after radical cystectomy.
    Yu A; Mansure JJ; Solanki S; Siemens DR; Koti M; Dias ABT; Burnier MM; Brimo F; Kassouf W
    PLoS One; 2018; 13(10):e0205746. PubMed ID: 30308033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LCK and CD3E Orchestrate the Tumor Microenvironment and Promote Immunotherapy Response and Survival of Muscle-Invasive Bladder Cancer Patients.
    Zheng X; Liao X; Nie L; Lin T; Xu H; Yang L; Shen B; Qiu S; Ai J; Wei Q
    Front Cell Dev Biol; 2021; 9():748280. PubMed ID: 35004669
    [No Abstract]   [Full Text] [Related]  

  • 7. Comprehensive analysis reveals a prognostic and therapeutic biomarker CD3D in the breast carcinoma microenvironment.
    Zhu Z; Ye W; Wu X; Lin S; Xu J; Li L; Li J; Wang H; Huang Z
    Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33350431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of tumor-infiltrating immune cells in muscle-invasive bladder cancer.
    Peng YL; Wu ZS; Lu HM; Wei WS; Xiong LB; Yu CP; Liu ZF; Li XD; Jiang LJ; Li YH; Liu ZW; Zhang ZL; Zhou FJ
    Am J Transl Res; 2020; 12(10):6524-6536. PubMed ID: 33194049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD3D is associated with immune checkpoints and predicts favorable clinical outcome in colon cancer.
    Yang Y; Zang Y; Zheng C; Li Z; Gu X; Zhou M; Wang Z; Xiang J; Chen Z; Zhou Y
    Immunotherapy; 2020 Jan; 12(1):25-35. PubMed ID: 31914842
    [No Abstract]   [Full Text] [Related]  

  • 10. Infiltration of CD3⁺ and CD68⁺ cells in bladder cancer is subtype specific and affects the outcome of patients with muscle-invasive tumors.
    Sjödahl G; Lövgren K; Lauss M; Chebil G; Patschan O; Gudjonsson S; Månsson W; Fernö M; Leandersson K; Lindgren D; Liedberg F; Höglund M
    Urol Oncol; 2014 Aug; 32(6):791-7. PubMed ID: 24794251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and validation of an excellent prognosis subtype of muscle-invasive bladder cancer patients with intratumoral CXCR5
    Huang Q; Zhou Q; Zhang H; Liu Z; Zeng H; Chen Y; Qu Y; Xiong Y; Wang J; Chang Y; Xia Y; Wang Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Wang Z; Bai Q; Zhang W
    Oncoimmunology; 2020 Aug; 9(1):1810489. PubMed ID: 32939328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Classification of Muscle-Invasive Bladder Cancer Based on Immunogenomic Profiling.
    Zhou X; Qiu S; Nie L; Jin D; Jin K; Zheng X; Yang L; Wei Q
    Front Oncol; 2020; 10():1429. PubMed ID: 32974156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and validation of poor prognosis immunoevasive subtype of muscle-invasive bladder cancer with tumor-infiltrating podoplanin
    Zhou Q; Wang Z; Zeng H; Zhang H; Liu Z; Huang Q; Wang J; Chang Y; Bai Q; Liu L; Zhu Y; Xu L; Dai B; Guo J; Xia Y; Wang Y; Xu J
    Oncoimmunology; 2020 Apr; 9(1):1747333. PubMed ID: 33457092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stromal LAG-3
    Zeng H; Zhou Q; Wang Z; Zhang H; Liu Z; Huang Q; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Xu L; Dai B; Guo J; Liu L; Zhu Y; Xu J
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32540859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral IL22-producing cells define immunoevasive subtype muscle-invasive bladder cancer with poor prognosis and superior nivolumab responses.
    Zeng H; Liu Z; Wang Z; Zhou Q; Qi Y; Chen Y; Chen L; Zhang P; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Dai B; Guo J; Xu L; Zhang W; Xu J
    Int J Cancer; 2020 Jan; 146(2):542-552. PubMed ID: 31584197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4
    Kristensen LK; Fröhlich C; Christensen C; Melander MC; Poulsen TT; Galler GR; Lantto J; Horak ID; Kragh M; Nielsen CH; Kjaer A
    Theranostics; 2019; 9(26):8221-8238. PubMed ID: 31754392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast.
    Rathore AS; Kumar S; Konwar R; Makker A; Negi MP; Goel MM
    Indian J Med Res; 2014 Sep; 140(3):361-9. PubMed ID: 25366203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer.
    Wang K; Shen T; Siegal GP; Wei S
    Hum Pathol; 2017 Nov; 69():110-117. PubMed ID: 28993275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mismatch Repair Status of Gastric Cancer and Its Association with the Local and Systemic Immune Response.
    Shin SJ; Kim SY; Choi YY; Son T; Cheong JH; Hyung WJ; Noh SH; Park CG; Kim HI
    Oncologist; 2019 Sep; 24(9):e835-e844. PubMed ID: 30894409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Composition and Clinical Impact of the Immunologic Tumor Microenvironment in Oral Squamous Cell Carcinoma.
    Boxberg M; Leising L; Steiger K; Jesinghaus M; Alkhamas A; Mielke M; Pfarr N; Götz C; Wolff KD; Weichert W; Kolk A
    J Immunol; 2019 Jan; 202(1):278-291. PubMed ID: 30530592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.